This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruilope, L. M. Articles by Romero, J. C. Search for Related Content PubMed PubMed Citation Articles by Ruilope, L. M. Articles by Romero, J. C.

Hypertension, Vol 8, 677-684, Copyright © 1986 by American Heart Association

ARTICLES

Effects of long-term treatment with indomethacin on renal function

LM Ruilope, R Garcia Robles, C Paya, JM Alcazar, E Miravalles, J Sancho-Rof, J Rodicio, FG Knox and JC Romero

The prolonged effects (42 days) of indomethacin treatment on the renin- angiotensin-aldosterone axis, renal hemodynamics, and renal excretory function in humans were studied. Indomethacin produced a 41% sustained depression in the 24-hour excretion of prostaglandin E2 and a mild (7%) decrease in inulin clearance but did not affect the clearance of p- aminohippurate, the 24-hour excretion of sodium and potassium, or the basal values of plasma aldosterone; however, it decreased the basal values of renin and prevented the stimulated (3 hours of walking) responses of plasma renin activity and plasma aldosterone. Indomethacin also produced a decrease in both the diuretic and saluretic response to furosemide and in the renal ability to concentrate urine. The indomethacin-induced hyporeninism and hypoaldosteronism were more pronounced when the subjects were receiving a sodium-restricted diet. This finding indicates that prolonged administration of anti- inflammatory drugs induces chronic hyporeninism and hypoaldosteronism. Prolonged treatment with indomethacin also produced some of the symptoms of a syndrome of hypoprostaglandinism, such as decreased plasma renin activity, plasma aldosterone, and urinary prostaglandin E2 in association with increases in plasma potassium levels and diastolic pressure.

This article has been cited by other articles:

				F. Roig, M. T. Llinas, R. Lopez, and F. J. Salazar Role of Cyclooxygenase-2 in the Prolonged Regulation of Renal Function Hypertension, November 1, 2002; 40(5): 721 - 728. [Abstract] [Full Text] [PDF]

				J. D. Gonzalez, M. T. Llinas, E. Nava, L. Ghiadoni, and F. J. Salazar Role of Nitric Oxide and Prostaglandins in the Long-term Control of Renal Function Hypertension, July 1, 1998; 32(1): 33 - 38. [Abstract] [Full Text] [PDF]

				J. D. Krier and J. C. Romero Systemic inhibition of nitric oxide and prostaglandins in volume-induced natriuresis and hypertension Am J Physiol Regulatory Integrative Comp Physiol, January 1, 1998; 274(1): R175 - R180. [Abstract] [Full Text] [PDF]

				T. Kato, S. Yoneda, M. Koketsu, and T. Fujinami Effects of Prostacyclin Infusion on Blood Pressure and Plasma Renin Activity in Patients with Essential Hypertension Angiology, February 1, 1992; 43(2): 110 - 120. [Abstract] [PDF]